Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib

Abstract

In 2014, the FDA approved two drugs for idiopathic pulmonary fibrosis that posed a regulatory challenge: the primary efficacy variable studied was the change in forced vital capacity, which hadn't been established as a surrogate for clinically meaningful benefit.